Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer

In preclinical studies, selenite had single agent activity and radiosensitized tumors in vivo. Here we report results from a Phase 1 trial in 15 patients with metastatic cancer treated with selenite (5.5 to 49.5 mg) orally as a single dose 2 hours before each radiation therapy (RT) treatment. Patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Knox, Susan J., Jayachandran, Priya, Keeling, Christine A., Stevens, Kathryn J., Sandhu, Navjot, Stamps-DeAnda, Stacy Leanne, Savic, Rada, Shura, Lei, Buyyounouski, Mark K., Grimes, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717060/
https://www.ncbi.nlm.nih.gov/pubmed/31454725
http://dx.doi.org/10.1016/j.tranon.2019.08.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717060/
https://www.ncbi.nlm.nih.gov/pubmed/31454725
http://dx.doi.org/10.1016/j.tranon.2019.08.006

Ejemplares similares